![<?echo $_SERVER['SERVER_NAME'];?>](/template/twentyseventeen/skin/images/header.jpg)
In recent years, China's level of industrialization of traditional Chinese medicine has gained certain improvements. However, there are still many shortcomings in many aspects such as industrial innovation capacity and support capacity, which seriously restricts the sustainable development of the Chinese medicine industry. The author believes that there are mainly the following problems:
Insufficient innovation capacity of Chinese medicine, innovation system needs further improvement. For a long time, due to the lack of basic research and innovation capabilities of Chinese medicine, the development of structural imbalances, especially in the inheritance and innovation of traditional Chinese medicine decoction processing technology, traditional Chinese medicine technical standards and safety guarantee system, traditional Chinese medicine accessories technology system, secondary development of famous big products, etc. The new varieties of traditional Chinese medicines have poor market competitiveness, and the traditional varieties have a weak growth.
There is not enough supportive capacity for sustainable use of TCM resources. Due to the serious destruction of traditional Chinese medicine resources and the prominent problem of resource loss, coupled with the unreasonable layout of Chinese herbal medicine bases, the absence of regulatory bodies, the unclear responsibilities and rights of resource protection, the unclear input of Chinese medicine resources protection, and poor financing channels, resulting in the lack of resource-based data and resource monitoring. Incomplete networks and resource alert mechanisms have not yet been established. With the expansion of the scale of industrialization, the issue of sustainable and rational use of resources will become increasingly prominent, affecting the sustainable development of the industry.
The ability of Chinese medicine to prevent and treat major diseases needs to be strengthened. China faces the dual threat of infectious diseases and chronic noncommunicable diseases. The incidence of major diseases such as cardiovascular and cerebrovascular diseases, malignant tumors, liver diseases, depression, diabetes, and menopausal syndrome has risen sharply. HIV, viral hepatitis, influenza, and other viruses Sexual diseases have seriously threatened the health of the people. Although this has given rise to opportunities for the development of traditional Chinese medicine, basic research input and weak innovation capabilities have seriously affected the effective use of Chinese medicine in this round of competition.
The lack of "flagship" companies, leading companies have poor radiation capabilities, and weak international competitiveness. Although China's TCM industry maintains a relatively high growth rate, the TCM industry has a weak foundation, and profit growth is limited by operating companies under the government's mandatory price cuts. Enterprises have consciously intensified their awareness of technological innovation, core competitiveness, and actively participate in international competition. The “flagship†type of Chinese medicine enterprise groups and industrial clusters with high industrial concentration are forming slowly. Under the global economic integration and increasingly fierce international competition, the development of Chinese medicine industry will face unprecedented pressure.
Insufficient innovation capacity of Chinese medicine, innovation system needs further improvement. For a long time, due to the lack of basic research and innovation capabilities of Chinese medicine, the development of structural imbalances, especially in the inheritance and innovation of traditional Chinese medicine decoction processing technology, traditional Chinese medicine technical standards and safety guarantee system, traditional Chinese medicine accessories technology system, secondary development of famous big products, etc. The new varieties of traditional Chinese medicines have poor market competitiveness, and the traditional varieties have a weak growth.
There is not enough supportive capacity for sustainable use of TCM resources. Due to the serious destruction of traditional Chinese medicine resources and the prominent problem of resource loss, coupled with the unreasonable layout of Chinese herbal medicine bases, the absence of regulatory bodies, the unclear responsibilities and rights of resource protection, the unclear input of Chinese medicine resources protection, and poor financing channels, resulting in the lack of resource-based data and resource monitoring. Incomplete networks and resource alert mechanisms have not yet been established. With the expansion of the scale of industrialization, the issue of sustainable and rational use of resources will become increasingly prominent, affecting the sustainable development of the industry.
The ability of Chinese medicine to prevent and treat major diseases needs to be strengthened. China faces the dual threat of infectious diseases and chronic noncommunicable diseases. The incidence of major diseases such as cardiovascular and cerebrovascular diseases, malignant tumors, liver diseases, depression, diabetes, and menopausal syndrome has risen sharply. HIV, viral hepatitis, influenza, and other viruses Sexual diseases have seriously threatened the health of the people. Although this has given rise to opportunities for the development of traditional Chinese medicine, basic research input and weak innovation capabilities have seriously affected the effective use of Chinese medicine in this round of competition.
The lack of "flagship" companies, leading companies have poor radiation capabilities, and weak international competitiveness. Although China's TCM industry maintains a relatively high growth rate, the TCM industry has a weak foundation, and profit growth is limited by operating companies under the government's mandatory price cuts. Enterprises have consciously intensified their awareness of technological innovation, core competitiveness, and actively participate in international competition. The “flagship†type of Chinese medicine enterprise groups and industrial clusters with high industrial concentration are forming slowly. Under the global economic integration and increasingly fierce international competition, the development of Chinese medicine industry will face unprecedented pressure.
Our spark plug products are ranged into more than 100 models with an anual out put of 6 million pcs. Besides the advanced technology,we also have a strong advantage of automatical production.Most of our production device is automatical that we have very high,efficiency and stable quality.
Main Markets: Mid East,Eastern Europe,South America,North America,Western Europe,Central America,Eastern Asia,South Asia,Southeast Asia,Africa,Domestic Market
Main products: spark plug,Brake Pads,filter
Car Spark Plug,Auto Spark Plug,Auto Light Spark Plugs,Supercheap Auto Spark Plugs
LIXIN INDUSTRIAL & TRADE CO.,Limited , https://www.jmmotorplugs.com